PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF LCZ696, A NOVEL DUAL-ACTING ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNI)

被引：0
|
作者：
Gu, J.
Noe, A.
Chandra, R.
Al-Fayoumi, S.
Ligueros, M. [1 ]
Sarangapani, R. [1 ]
Maahs, S.
Ksander, G.
Rigel, D.
Jeng, A.
Dole, W.
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF HYPERTENSION | 2009年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：S9 / S9
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)
    Gu, Jessie
    Noe, Adele
    Chandra, Priya
    Al-Fayoumi, Suliman
    Ligueros-Saylan, Monica
    Sarangapani, Ramesh
    Maahs, Suzanne
    Ksander, Gary
    Rigel, Dean F.
    Jeng, Arco Y.
    Lin, Tsu-Han
    Zheng, Weiyi
    Dole, William P.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (04): : 401 - 414
  • [2] Efficacy of LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI), in obese and overweight subjects with hypertension
    Ruilope, L. M.
    Izzo, J. L., Jr.
    Conde, L. G.
    Zappe, D. H.
    Zhang, Y.
    Zhang, J.
    EUROPEAN HEART JOURNAL, 2014, 35 : 65 - 65
  • [3] Clinic blood pressure in stable heart failure patients treated with the dual-acting neprilysin and angiotensin receptor inhibitor LCZ696
    Kobalava, Z.
    Kotovskaya, Y.
    Meray, I.
    Globenko, A.
    Moiseev, V.
    Albrecht, D.
    Feng, A.
    Chandra, P.
    Jordaan, P.
    EUROPEAN HEART JOURNAL, 2011, 32 : 788 - 788
  • [4] LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
    Martin P Lefkowitz
    BMC Pharmacology and Toxicology, 16 (Suppl 1)
  • [5] Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan (LCZ696), a dual-acting angiotensin receptor-neprilysin inhibitor
    Ushijima, Kentaro
    Ando, Hitoshi
    Arakawa, Yusuke
    Aizawa, Kenichi
    Suzuki, Chisato
    Shimada, Ken
    Tsuruoka, Shu-ichi
    Fujimura, Akio
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2017, 5 (04):
  • [6] Comparative efficacy of valsartan and LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI), in hypertensive individuals: effects of gender
    Ruilope, L. M.
    Izzo, J. L., Jr.
    Conde, L. G.
    Zappe, D. H.
    Zhang, Y.
    Zhang, J.
    EUROPEAN HEART JOURNAL, 2014, 35 : 571 - 571
  • [7] Angiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial hypertension?
    Katsi, Vasiliki
    Skalis, Georgios
    Pavlidis, Antonis N.
    Makris, Thomas
    Nihoyannopoulos, Petros
    Tousoulis, Dimitris
    Kallikazaros, Ioannis
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2015, 1 (04) : 260 - 264
  • [8] LCZ696: a dual-acting sodium supramolecular complex
    Feng, Lili
    Karpinski, Piotr H.
    Sutton, Paul
    Liu, Yugang
    Hook, David F.
    Hu, Bin
    Blacklock, Thomas J.
    Fanwick, Philip E.
    Prashad, Mahavir
    Godtfredsen, Sven
    Ziltener, Christoph
    TETRAHEDRON LETTERS, 2012, 53 (03) : 275 - 276
  • [9] Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor
    Gan, Lu
    Langenickel, Thomas
    Petruck, Jesika
    Kode, Kiran
    Rajman, Iris
    Chandra, Priya
    Zhou, Wei
    Rebello, Sam
    Sunkara, Gangadhar
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (01): : 78 - 86
  • [10] Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor
    Ayalasomayajula, Surya
    Langenickel, Thomas
    Pal, Parasar
    Boggarapu, Sreedevi
    Sunkara, Gangadhar
    CLINICAL PHARMACOKINETICS, 2017, 56 (12) : 1461 - 1478
12345